证券代码：833266 证券简称：生物谷 公告编号：2025-031 4.发出监事会会议通知的时间和方式：2025 年 4 月 15 日 以通讯方 式发出 5.会议主持人：监事会主席许晓森先生 6.召开情况合法、合规、合章程性说明： 云南生物谷药业股份有限公司 第五届监事会第四次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 4 月 25 日 2.会议召开地点：上海市浦东新区浦明路 898 号海航大厦 9 楼会议 室 3.会议召开方式：现场 本次会议的召集、召开及议案审议程序符合《公司法》及《公司 章程》的相关规定，会议的召集、召开及表决合法有效。 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 二、议案审议情况 （一）审议通过《关于 2024 年度监事会工作报告》议案 1.议案内容： 公司监事会 2024 年度认真履行《公司法》《公司章程》赋予的 职权，严格执行股东会决议，有效发挥了监事 ...

1、信永中和会计师事务所（特殊普通合伙）因原控股股东深圳 市金沙江投资有限公司（以下简称"金沙江"）尚未归还公司全部占 用资金，且原实际控制人林艳和及原控股股东金沙江存在大额逾期债 务，致使其无法获取充分、适当的审计证据判断生物谷管理层 2024 年度对上述应收款项计提的信用减值损失金额是否恰当，而出具的保 留意见审计报告真实、客观地反映了公司 2024 年度的财务状况和经 营情况，董事会出具的专项说明充分揭示了公司面临的风险，监事会 对该专项说明无异议。 2、公司监事会将依法履行监督职责，持续督促公司董事会和管 理层切实采取有效措施，努力降低和消除所涉事项对公司的不利影响， 切实维护公司及全体股东特别是中小股东的合法权益，保证公司持续、 稳定、健康发展。 云南生物谷药业股份有限公司 证券代码：833266 证券简称：生物谷 公告编号：2025-028 云南生物谷药业股份有限公司 监事会对《董事会关于 2024 年度保留意见审计报告 涉及事项的专项说明》的意见 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带 法律责 ...

证券代码：833266 证券简称：生物谷 公告编号：2025-006 云南生物谷药业股份有限公司 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 4 月 25 日 2.会议召开地点：上海市浦东新区浦明路 898 号海航大厦 9 楼 会议室 3.会议召开方式：现场及通讯方式 4.发出董事会会议通知的时间和方式：2025 年 4 月 15 日以通讯 方式发出 5.会议主持人：董事长林弘威先生 6.会议列席人员：公司监事及高级管理人员 第五届董事会第四次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 7.召开情况合法、合规、合章程性说明： 本次会议的召集、召开及议案审议程序符合《公司法》及《公司 章程》的相关规定，会议的召集、召开及表决合法有效。 （二）会议出席情况 会议应出席董事 9 人，出席和授权出席董事 9 人。 董事胡云华以通讯方式参与表决。 二、议案审议情况 （一）审议通过《关于 2024 年度董事会工作报告的议案》 1.议案内容： 2024年度，公司董事会 ...

国新证券股份有限公司 (一) 风险事项类别 | 序号 | 类别 | 风险事项 | 公司是否履行信 息披露义务 | | --- | --- | --- | --- | | | 公司治理 | 原控股股东占用公司资金 | 是 | | 2 | 其他 | 财务报告被出具保留意见 | 是 | (二) 风险事项情况 1、公司原控股股东存在占用公司资金的情况: 公司原控股股东深圳市金沙江投资有限公司(以下简称"金沙江投资公司") 通过生物谷公司对第三方背书银行承兑汇票的方式占用公司资金,其中 2021 年 度占用资金 67,115,237.50元,归还资金 39,061,315.34元,2022年1月份占用资 金 11.649.139.54元,归还资金 39.703.061.70元;金沙江投资公司通过生物谷委 托第三方理财的方式占用公司资金,其中 2021 年度占用资金 122,000,000.00元, 2022 年 1 月份至 3 月份占用资金 155,000,000.00 元。截至 2024年财务报表批准 报出日，金沙江投资公司尚未归还生物谷资金合计 257,000,000.00 元。 2、信永中和会计师事务所对生物谷 ...

Financial Performance - Operating revenue for the first quarter of 2025 was CNY 92,118,348.63, down 40.35% year-on-year [10]. - Net profit attributable to shareholders for the first quarter of 2025 was a loss of CNY 16,768,203.83, representing a decline of 259.25% compared to the same period last year [10]. - Basic earnings per share for the first quarter of 2025 was -CNY 0.14, a decrease of 275.00% year-on-year [10]. - The company's cash flow from operating activities for the first quarter of 2025 was -CNY 24,104,184.81, a decline of 144.49% compared to the previous year [10]. - Total operating revenue for Q1 2025 was CNY 92,118,348.63, a decrease from CNY 154,441,052.85 in Q1 2024 [50]. - Net profit for Q1 2025 was a loss of CNY 16,768,203.83, while Q1 2024 reported a net profit of CNY 10,529,264.31 [51]. - The total comprehensive income for Q1 2025 was a loss of ¥17,389,376.69, compared to a comprehensive income of ¥9,570,421.92 in Q1 2024 [54]. Assets and Liabilities - Total assets as of March 31, 2025, were CNY 1,112,800,070.14, a decrease of 2.82% compared to the end of the previous year [10]. - The asset-liability ratio for the consolidated entity was 18.38%, down from 19.21% at the end of the previous year [10]. - Total current assets decreased from ¥546,033,405.54 in 2024 to ¥513,462,121.01 in 2025, a decline of approximately 5.93% [44]. - Total liabilities decreased from ¥219,970,089.73 in 2024 to ¥204,490,988.67 in 2025, a reduction of approximately 7.06% [46]. - Total equity attributable to shareholders decreased from ¥925,077,285.30 in 2024 to ¥908,309,081.47 in 2025, a decline of about 1.81% [46]. Shareholder Information - The largest shareholder, Shanghai Xinhong Pharmaceutical Co., Ltd., holds 32,851,219 shares, accounting for 26.49% of total shares [20]. - The total number of shareholders with more than 5% ownership is 10, collectively holding 65,807,461 shares, which is 53.06% of total shares [21]. - The total number of unrestricted shares increased from 76,935,090 to 76,990,252, representing a change of 55,162 shares, which is an increase of 0.07% [20]. - The total number of restricted shares decreased from 47,064,917 to 47,009,755, reflecting a change of -55,162 shares, which is a decrease of 0.15% [20]. Cash Flow and Expenses - The company reported a total cash inflow from operating activities of ¥106,460,668.56 in Q1 2025, compared to ¥189,066,154.08 in Q1 2024, a decrease of 43.6% [57]. - The cash flow from operating activities for Q1 2025 was negative at -¥24,104,184.81, contrasting with a positive cash flow of ¥54,184,916.38 in Q1 2024 [56]. - The company incurred sales expenses of ¥41,526,778.03 in Q1 2025, a decrease of 54.7% from ¥91,567,552.81 in Q1 2024 [53]. - Research and development expenses were ¥2,915,757.96 in Q1 2025, slightly up from ¥2,697,325.40 in Q1 2024, reflecting an 8.1% increase [53]. Related Party Transactions and Legal Issues - The company has engaged in related party transactions amounting to ¥166,696.74 for utility payments to Yunnan Biopharmaceutical Co., Ltd. and ¥754,652.00 for product sales to Longyan Pianzaihuang Hongren Pharmaceutical Co., Ltd. [35]. - The company has filed a civil lawsuit against Jinsha River and Lin Yanhe regarding the fund occupation, which is currently in the legal process [30]. - The company has maintained communication with Jinsha River and Lin Yanhe to resolve the fund occupation issue [38]. - The Guangdong High Court upheld the lower court's ruling, concluding the case regarding the fund occupation [31]. Fund Occupation and Recovery Efforts - The company reported that the controlling shareholder, Shenzhen Jinsanjiang Investment Co., Ltd., occupied funds totaling 257 million yuan, which have not yet been repaid [28]. - As of March 31, 2025, the controlling shareholder has repaid 20 million yuan of the occupied funds [29]. - The company has taken measures to recover the remaining occupied funds of 257 million yuan and corresponding returns [29]. - The company has implemented measures to prevent dividend distribution to Jinsha River and Lin Yanhe until they fulfill their commitments [40]. - The company has accrued bad debts totaling ¥195.32 million due to unreturned funds [32].

Company Recognition and Achievements - In 2024, the company was recognized as a leading enterprise in high-quality development in the Chinese pharmaceutical industry, with its product, Dengzhanhua Jiangong, awarded as a top brand[5]. - The company ranked 89th in the 2023 Top 100 Chinese Traditional Medicine Enterprises list[6]. - The company's product, Dengzhanhua Xixin, was included in the "Green Yunnan Products" brand directory in September 2024[9]. - The company was listed among the top 100 manufacturing enterprises in Yunnan in 2024[10]. Financial Performance - The company's operating revenue for 2024 was ¥516,232,107.07, a decrease of 17.05% compared to ¥622,338,700.67 in 2023[32]. - The net profit attributable to shareholders for 2024 was -¥74,400,964.91, representing a decline of 509.83% from -¥12,200,282.05 in 2023[32]. - The gross profit margin decreased to 72.89% in 2024 from 80.94% in 2023[32]. - Total assets at the end of 2024 were ¥1,145,047,375.03, down 7.34% from ¥1,235,702,221.84 at the end of 2023[34]. - The total liabilities decreased by 6.88% to ¥219,970,089.73 in 2024 from ¥236,223,971.63 in 2023[34]. - The net assets attributable to shareholders decreased to ¥925,077,285.30 in 2024, a reduction of 7.44% from ¥999,478,250.21 in 2023[34]. - The cash flow from operating activities for 2024 was ¥39,967,466.89, a significant decrease of 65.15% compared to ¥114,686,505.28 in 2023[34]. - The basic earnings per share for 2024 was -¥0.60, a decline of 500.00% from -¥0.10 in 2023[32]. Operational Developments - In August 2024, the company established a wholly-owned subsidiary in Shanghai to enhance its comprehensive value and sustainable development[8]. - The company relocated its registered address to Yunnan Province in February 2024[7]. - The company completed the cancellation of 3,999,993 shares, reducing the total shares from 128,000,000 to 124,000,007[26]. - The company has 7 products in the Dengzhanhua series, with Dengzhan Shengmai capsules and Dengzhan Xixin injection being the main patented products[42]. Research and Development - The company is focusing on establishing high-level R&D collaborations with prestigious medical institutions to drive innovation and improve patient care[51]. - The company aims to improve product clinical value and market competitiveness through ongoing R&D projects[100]. - The company has established collaborations with hospitals for RCT studies, enhancing its research capabilities and product validation[101]. - The company holds a total of 48 patents, all of which are invention patents, indicating a strong focus on innovation[98]. Market Strategy and Expansion - The company plans to expand its market presence by exploring new markets along the "Belt and Road" initiative and enhancing digital marketing strategies[48]. - The company aims to achieve double growth in operating income and profit by optimizing resource allocation and enhancing operational efficiency in response to the complex market environment[59]. - The company aims to strengthen the entire industrial chain of the medicinal plant, Dan Zhan Hua, to ensure raw material availability and promote high-quality development[121]. - The company plans to enhance market share of its core products, Dan Zhan Sheng Mai capsules and Dan Zhan Xi Xin injections, by expanding into untapped markets and improving coverage in grassroots medical institutions[122]. Legal and Compliance Issues - The company is actively addressing issues related to fund occupation, ensuring legal rights are protected, and is in the process of pursuing legal actions against former controlling shareholders for the return of misappropriated funds[54][55]. - The company has ongoing litigation with a total claim amount of 273,107,940.57 yuan, with the first instance ruling against the company[146]. - The company has taken measures to recover the remaining occupied funds of 257 million yuan and corresponding returns[160]. - The company has initiated legal proceedings against Jinsha River and related parties, with the first instance court ruling against the company[148]. Environmental and Social Responsibility - The company is committed to environmental responsibility, ensuring compliance with pollution discharge standards and passing external inspections[50]. - The company has promoted the planting area of Dengzhanhua in Yunnan Province to over 3,000 mu, contributing to poverty alleviation and rural revitalization[108]. - The company sponsored 20,000 yuan for the "2024 Mile Women's Half Marathon" to support local cultural and sports development[108]. - The company adheres to environmental protection regulations and has implemented measures to ensure wastewater discharge is below permitted levels[110]. Challenges and Risks - The company is facing risks of core technical personnel loss during the relocation of its production base from Kunming to Mile, which may impact long-term development[135]. - The price of traditional Chinese medicine materials has significantly increased due to various factors, which will affect the production costs of related products[136]. - The company has accumulated a bad debt provision of 195.32 million yuan due to unreturned funds, with credit impairment losses increasing by 45.63% year-on-year[148]. - The company has faced significant cash flow and operational impacts due to the large amount of funds occupied by the defendants[148]. Corporate Governance - The company has a total of 9 board members, 3 supervisors, and 2 senior management personnel[199]. - The total remuneration for the chairman and general manager, Lin Hongwei, is 26.65 million yuan[198]. - The total remuneration for the general manager, Yang Zhiling, is 53.48 million yuan[198]. - The total remuneration for the vice general manager, Zhang Chuan Kai, is 88.13 million yuan[198].

关于拟设立上海分公司的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 云南生物谷药业股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开第五届董事会第四次会议，审议通过了《关于拟设立上 海分公司的议案》。根据《公司章程》及相关规定，本次议案无需提 交公司股东会审议。 一、拟设立分公司的基本情况 分公司的名称：云南生物谷药业股份有限公司上海分公司 类型：股份有限公司分公司 分公司负责人：胡建辉 分公司经营场所：具体以当地市场监督管理部门登记为准 证券代码：833266 证券简称：生物谷 公告编号：2025-034 云南生物谷药业股份有限公司 二、设立分公司的目的 本次设立分公司，为借助上海的区位、人才及资本优势，进一步 提升公司相关业务的经营管理效率和综合竞争力，对公司未来的发展 具有积极的意义。 三、设立分公司对公司经营的影响及潜在的风险 本次设立分公司，符合公司经营发展需要，不会对公司的财务和 经营情况产生重大不利影响，不存在损害公司及股东利益的情形。 本次设立分公司的事宜经公 ...

证券代码：833266 证券简称：生物谷 公告编号：2025-021 云南生物谷药业股份有限公司 关于会计师事务所 2024 年度履职情况评估报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带 法律责任。 云南生物谷药业股份有限公司（以下简称"公司"）聘请了信永 中和会计师事务所（特殊普通合伙）（以下简称"信永中和会计师事 务所"）作为公司 2024 年度财务报表审计机构。根据《中华人民共 和国公司法》《中华人民共和国证券法》《上市公司治理准则》《国有 企业、上市公司选聘会计师事务所管理办法》等规定和要求，公司对 信永中和会计师事务所在近一年审计中的履职情况进行了评估，具体 情况如下： 一、资质条件 （一）基本信息 截至 2024 年 12 月 31 日，信永中和合伙人（股东）259 人，注册 会计师 1,780 人。签署过证券服务业务审计报告的注册会计师人数超 过 700 人。 名称：信永中和会计师事务所（特殊普通合伙） 成立日期：2012 年 3 月 2 日； 组织形式：特殊普通合伙企业； 注册地址：北京市东 ...

关于预计 2025 年日常性关联交易的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律责任。 一、 日常性关联交易预计情况 | | | 单位：元 | 关联交易类别 | 主要交易内容 | 预计 2025 年 | （2024）年与关联 | 预计金额与上年实际发 | | --- | --- | --- | --- | --- | | | | 发生金额 | 方实际发生金额 | 生金额差异较大的原因 | | 购买原材料、 燃料和动力、 | - | - | - | - | | 接受劳务 | | | | | | 销售产品、商 | 委托关联方销售公司 | 4,000,000 | 388,000 | 2025 年系根据实际交 | | 品、提供劳务 | 产品 | | | 易需求进行预计 | | 委托关联方销 售产品、商品 | - | - | - | - | | 接受关联方委 托代为销售其 | - | - | - | - | | 产品、商品 | | | | | | 其他 | 代付水电费，支付水 电费后收回代垫款 | 800,00 ...

专项说明 | 索引 页码 | | --- | | 专项说明 1-2 | | 非经营性资金占用及其他关联资金往来情况汇总表 3 | 关于云南生物谷药业股份有限公司 2024 年度非经营性资金占用及其他关联资金往来的专项说明 XYZH/2025SZAA8B0213 云南生物谷药业股份有限公司 2024 年度 非经营性资金占用及其他关联资金往来的 本专项说明仅供生物谷公司为 2024 年度报告披露之目的使用，未经本事务所书面同 意，不得用于其他任何目的。 信永中和会计师事务所（特殊普通合伙） 中国注册会计师： 云南生物谷药业股份有限公司 云南生物谷药业股份有限公司全体股东： 我们按照中国注册会计师审计准则审计了云南生物谷药业股份有限公司（以下简称生 物谷公司）2024 年度财务报表，包括 2024 年 12 月 31 日的合并及母公司资产负债表、2024 年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公司股东权益变动表以 及财务报表附注，并于 2025 年 4 月 25 日出具了 XYZH/2025SZAA8B0216 号保留意见的审计 报告。 根据《上市公司监管指引第 8 号——上市公司资金往来、对外 ...